Does D81.32 require prior authorization?

No, D81.32 does not require prior authorization (high confidence). Covered without prior authorization.

`D81.32`, Adenosine deaminase 2 deficiency

ICD-10-CM

No Prior Auth Required

Covered without prior authorization (high confidence)

Clinical records must clearly document the diagnosis, specific foot findings, and the clinical rationale that treatment was medically necessary and that withholding care would be hazardous to the beneficiary.
For the policy’s asterisked/complicating conditions, include the name of the primary physician (MD or DO) who made the diagnosis and the approximate date of the last visit; this information must be included in the medical record and entered on the appropriate claim forms or electronic equivalent when billing Medicare.
Follow CMS website instructions for billing Part A and Part B claims and Noridian guidance for JE Part B claims; include required claim form entries/electronic equivalents.
Document provider licensure and ensure services are rendered by a certified physician, podiatrist, or non-physician practitioner within scope of State licensure when billing for routine foot care.

Routine foot care is covered only when clinical documentation demonstrates the patient’s condition warrants the provider to render the services and that failure to provide the services would be hazardous to the beneficiary due to underlying medical condition(s), per CMS Pub 100-02, Ch.15, §290.
Respiratory pathogen panel testing is covered when performed in an outpatient, non-institutional Part B setting from a single biologic specimen on a single date of service and the order is not a reflex test.
Respiratory pathogen panel testing is covered when the medical record documents that the testing facility can deliver timely results and that the test results can reasonably be expected to change clinical management and improve patient health outcomes.
Respiratory pathogen panel testing is covered when performed as a single service from a single biologic specimen in the outpatient setting on a single date of service and is reasonable and necessary per LCD L38918.
The test is covered when performed in a Medicare Part B setting that is equipped to deliver timely results and when the results can reasonably be expected to lead to a change in clinical management that improves health outcomes.
Molecular syndromic infectious disease panels are covered when billed with the appropriate proprietary CPT®/PLA code (or CPT® 87999 if no specific code exists) and accompanied by ICD-10-CM diagnosis codes that support medical necessity documented in the patient record.

CGS-J15-L39038, MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

J15

CGS-J18-L39038, MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

J18

WPS-J5-L39044, MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

A58761, Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Ask Backwork about documentation requirements, denial risks, or coverage in your state.